Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist

Peptides

Volumn 18, Issue 8, 1997, Pages 1223-1227

  Sarhan, Shakir ^a   Hitchcock, Janice M ^a   Grauffel, Christine A ^a   Wettstein, Joseph G ^a  

^a CNS Research   (United States)

Author keywords

Amphetamine; Analgesia; Catalepsy; Dopamine; Eisai hexapeptide; Locomotor activity; Neurotensin; NT 1; Phencyclidine; Schizophrenia

Indexed keywords

AMPHETAMINE; EISAI PEPTIDE; HEXAPEPTIDE; NALOXONE; NEUROTENSIN; NT 1; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG ACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS;

ANALGESICS; ANIMALS; ANTIPSYCHOTIC AGENTS; BODY TEMPERATURE; CATALEPSY; MALE; MICE; MOTOR ACTIVITY; NEUROTENSIN; OLIGOPEPTIDES; PAIN MEASUREMENT; RECEPTORS, NEUROTENSIN;

ANIMALIA; VIBRIO PHAGE NT-1;

EID: 0031458706     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00145-9     Document Type: Article

References (30)

1. αMethyl-Arg-Lys-Pro-Trp-TIe-Leu (NT1). Biochem. Pharmacol. 49:1995;1147-1157.
2. Barbaz B. S., Autry W. L., Ambrose F. G., Hall N. R., Liebman J. M. Antinociceptive profile of sulfated CCK-8. Comparison with CCK-4, unsulfated CCK-8 and other neuropeptides. Neuropharmacology. 25:1986;823-829.
3. Berry S. C., Lodge D. Benz(f)isoquinolines as excitatory amino acid antagonists An indication of their mechanism of action . Biochem. Pharmacol. 33:1984;3829-3832.
4. Bissette G., Nemeroff C. B., Loosen P. T., Prange A. J. Jr, Lipton M. A. Hypothermia and cold intolerance induced by the intracisternal administration of the hypothalamic peptide neurotensin. Nature. 262:1976;607-609.
5. Brown J., Handley S. L. The development of catalepsy in drug-free mice on repeated testing. Neuropharmacology. 19:1980;675-678.
6. Carraway R., Leeman S. E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248:1973;6854-6861.
7. Clineschmidt B. V., McGuffin J. C. Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli. Eur. J. Pharmacol. 49:1977;395-396.
8. Coguerel A., Dubuc I., Kitabgi P., Costentin J. Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin N. Neurochem. Int. 12:1988;361-366.
9. Cohen B. D., Rosenbaum G., Luby E. D., Gottlieb J. S. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Arch. Gen. Psychiatry. 6:1962;79-85.
10. Domino E. F. History and pharmacology of PCP and PCP-related drugs. J. Psychedel. Drugs. 12:1980;223-227.
11. Dunn A. J., Snijders R., Hurd R. W., Kramery N. R. Induction of catalepsy by central nervous system administration of neurotensin. Ann. NY Acad. Sci. 400:1982;345-353.
12. Handler C. M., Mondgock D. J., Zhao S. F., Geller E. B., Adler M. W. Interaction between opioid agonists and neurotensin on thermoregulation in the rat. I. Body temperature. J. Pharmacol. Exp. Ther. 274:1995;284-292.
13. Jackson D. M., Andén N. E., Dahlström A. A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain. Psychopharmacologia. 45:1975;139-149.
14. Jackson D. M., Johansson C., Lindgren L.-M., Bengtsson A. Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol. Biochem. Behav. 48:1994;465-471.
15. Javitt D. C., Zukin S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
16. Jolicoeur F. B., Barbeau A., Rioux F., Quirion R., St-Pierre S. Differential neurobehavioral effects of neurotensin and structural analogues. Peptides. 2:1981;171-176.
17. Labbé-Jullié C., Dubuc I., Brouard A., Doulut S., Bourdel E., Pelaprat D., Mazella J., Martinez J., Rostene W., Costentin J., Kitabgi B. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes. J. Pharmacol. Exp. Ther. 268:1994;328-336.
18. Maidment B. J., Siddall V. R., Erdelyi R. E., Evans C. J. Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain microdialysis combined with a sequential multiple antigen radioimmunoassay . Neuroscience. 45:1991;81-93.
19. 2A receptors. Eur. J. Pharmacol. 280:1995;9-11.
20. Nemeroff C. B. The interaction of neurotensin with dopaminergic pathways in the central nervous system Basic neurobiology and implications for the pathogenesis and treatment of schizophrenia . Psychoneuroendocrinology. 11:1986;15-37.
21. Nemeroff C. B., Luttinger D., Prange A. J. Neurotensin and bombesin. Iverson L. L., Iverson S. D., Snyder S. H. Handbook of psychopharmacology. vol. 16:1983;363-466 Plenum Press, New York.
22. Pugsely T. A., Akunne H. C., Whetzel S. Z., Demattos S. B., Corbin A. E., Wiley J. N., Wustrow D. J., Wise L. D., Heffner T. G. Differential effects of nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonist. Peptides. 16:1995;37-44.
23. Randall L. O., Selito J. J. A method for measurement of analgesic activity on inflamed tissue. Arch. Pharmacodyn. Ther. 11:1957;409-419.
24. Rivest R., Jolicoeur F. B., Marsden C. A. Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo. Neuropharmacology. 30:1991;25-33.
25. Ross S. B. The central stimulatory action of inhibitors of the dopamine uptake. Life Sci. 24:1979;159-186.
26. Seiler N., Grauffel C. Antagonism of phencyclidine-induced hyperactivity in mice by elevated brain GABA concentrations. Pharmacol. Biochem. Behav. 41:1992;603-606.
27. 2A antagonist in development for schizophrenia (abstract) (8th biennial winter workshop on schizophrenia, Crans Montana, Switzerland, March 16-22, 1996) . Schizophr. Res. 18:1996;2-3.
28. Steinberg R., Bougault I. M., Souilhac J., Rodier D., Mons G., Terranova J. P., Le Fur G., Soubrié P. SR48692, a non-peptide neurotensin receptor antagonist, differentially affects neurotensin-induced behavior and changes in dopaminergic transmission. Neurosci. 59:1994;921-929.
29. Vickroy T. W., Johnson K. M. Similar dopamine-releasing effects of phencyclidine and nonamphetamine stimulants in striatal slices. J. Pharmacol. Exp. Ther. 223:1982;669-674.
30. Wachtel H., Turski L. Glutamate A new target in schizophrenia? Trends Pharmacol. Sci. 11:1990;219-220.